ID | 118623 |
著者 |
Okano, Yoshio
National Hospital Organization Kochi Hospital
國重, 道大
National Hospital Organization Kochi Hospital
Kondo, Yoshihiro
National Hospital Organization Kochi Hospital
Kadota, Naoki
National Hospital Organization Kochi Hospital
森下, 敦司
National Hospital Organization Kochi Hospital
Naruse, Keishi
National Hospital Organization Kochi Hospital
Machida, Hisanori
National Hospital Organization Kochi Hospital
Hatakeyama, Nobuo
National Hospital Organization Kochi Hospital
Hino, Hiroyuki
National Hospital Organization Kochi Hospital
Takeuchi, Eiji
National Hospital Organization Kochi Hospital
|
キーワード | advanced squamous cell carcinoma of the lung
immune checkpoint inhibitor
induction immunochemotherapy
pathological complete response
|
資料タイプ |
学術雑誌論文
|
抄録 | Immune checkpoint inhibitors (ICIs) have caused a paradigm shift in the treatment of lung cancer. Here, we encountered a case of inoperable locally advanced squamous cell carcinoma of the lung that became operable with pembrolizumab-based immunochemotherapy and achieved a pathological complete response. An 82-year-old man suspected of having lung cancer was referred to our hospital. The patient was clinically diagnosed with left upper lobe squamous cell carcinoma cT2aN3M0 c-stage IIIC. Immunostaining revealed the expression of programmed death-ligand 1 in 60% of tumor cells. The cancer cells disappeared after two cycles of chemotherapy with carboplatin and nanoparticle albumin-bound paclitaxel plus pembrolizumab. As the abnormal accumulation of 18F-fluorodeoxyglucose (FDG) on FDG-positron emission tomography/computed tomography before chemotherapy almost disappeared after pembrolizumab-based immunochemotherapy, left upper lobectomy and lymph node dissection were performed. No cancer cells were pathologically detected from the resected tissue. Therefore, ICIs combined with chemotherapy may enable inoperable advanced lung cancer patients to undergo surgery and achieve a complete response.
|
掲載誌名 |
Thoracic Cancer
|
ISSN | 17597714
17597706
|
出版者 | China Lung Oncology Group|John Wiley & Sons Australia
|
巻 | 13
|
号 | 3
|
開始ページ | 510
|
終了ページ | 513
|
発行日 | 2021-12-20
|
権利情報 | This is an open access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
医学系
|